A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
This research study is testing a new medication called garetosmab for adults who have a rare condition called Fibrodysplasia Ossificans Progressiva, or FOP. FOP causes soft tissues in the body to turn into bone, which can cause pain and limit movement. The main goal is to see if garetosmab is safe to use and if it can help improve the symptoms of FOP. We'll also be looking at any potential side effects, how the body handles the drug, and if the body creates antibodies against it. This is a Phase 3 study, which means it's a key step before the drug might become widely available. Participants will either receive garetosmab or a placebo (a dummy drug).
Överblick
Vad handlar denna studie om?
This study is designed to explore a new drug called garetosmab for adults living with Fibrodysplasia Ossificans Progressiva (FOP). FOP is a very rare condition that causes extra bone to form in soft tissues like muscles, tendons, and ligaments. This extra bone can cause a lot of pain and severely limit movement, making everyday activities difficult.
The main purpose of this research is to see if garetosmab is a safe and effective treatment for FOP. We want to understand if it can help reduce the symptoms of FOP and improve the lives of those affected. To do this, some participants will receive the active drug, garetosmab, while others will receive a placebo, which looks like the drug but doesn't contain any active medicine. This allows researchers to fairly compare the effects of the new drug.
Throughout the study, the research team will carefully monitor participants. They will be looking for any side effects from the drug, how the body processes garetosmab, and whether the body's immune system reacts to it. All this information is crucial for understanding how the drug works and deciding if it could become a new treatment option for FOP in the future.
Viktiga punkter
- This study is for adults with Fibrodysplasia Ossificans Progressiva (FOP).
- It's testing a new drug called garetosmab against a placebo.
- The main goals are to check the drug's safety and how well it works.
- Deltagande innebär regelbundna klinikbesök, blodprov och skanningar.
- You might get the active drug or a dummy drug.
- Du kan sluta delta när som helst.
Vem kan vara berättigad?
To be considered for this study, you must be an adult aged 18 or older and have a confirmed diagnosis of Fibrodysplasia Ossificans Progressiva (FOP). This diagnosis needs to be based on specific findings, like typical changes in your big toes, episodes of swelling in soft tissues, or extra bone growth. We'll also need proof from a genetic test showing you have the specific gene change linked to FOP.
Crucially, you must have experienced some FOP activity within the last year before joining the study. This means you've had pain, swelling, stiffness, or other symptoms of FOP flare-ups, or that your joint movement has worsened, or X-rays have shown new or growing areas of extra bone.
There are also some reasons why you might not be able to join. For example, if your FOP is very advanced, if you have other serious health problems like severe heart, kidney, or liver conditions, or a history of cancer, you might not be eligible. Also, certain uncontrolled conditions like very high blood pressure or diabetes could prevent you from taking part, as these might make the study results unclear or put you at higher risk.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Är du 18 år eller äldre?
- Do you have a confirmed diagnosis of FOP, including a genetic test?
- Have you had FOP symptoms or progression in the last year?
- Are you able to have CT scans and other required medical procedures?
- Do you have any serious health conditions like severe heart disease or cancer?
- Is your diabetes or blood pressure well-controlled?
Vad innebär deltagande?
If you join this study, you'll be randomly assigned to receive either the study drug, garetosmab, or a placebo (a dummy drug) through an IV drip. You won't know which one you're getting. Regular visits to the clinic will be needed, where the study team will perform various assessments. These will likely include physical examinations, blood and urine tests, and detailed imaging scans, such as CT scans, to monitor your FOP and see how the medication is affecting you. You'll also be asked about any symptoms you're experiencing and any side effects. The total duration of your participation in the study, including the treatment period and follow-up, will be explained in full detail by the study team, but typically, Phase 3 trials can last for a year or more. You are free to withdraw from the study at any time.
Potentiella risker och fördelar
Platser (22)
- University of California Los Angeles (UCLA) Medical CenterVerifierat postnummerLos Angeles, USA
- Vanderbilt University Medical CenterVerifierat postnummerNashville, USA
- Royal North Shore HospitalVerifierat postnummerSt Leonards, Australia
- Hospital Israelita Albert EinsteinVerifierat postnummerSão Paulo, Brasilien
- Universidad de ConcepcionVerifierat postnummerConcepción, Chile
- Tongji Hospital of Tongji UniversityVerifierat postnummerShanghai, China
- Clinica Universidad de La SabanaVerifierat postnummerChía, Colombia
- HUS Children and Adolescents Park Hospital Clinical Trial UnitVerifierat postnummerHelsingfors, Finland
- Hôpital LapeyronieVerifierat postnummerMontpellier, Frankrike
- Hopital LariboisiereVerifierat postnummerParis, Frankrike
- Queen Mary HospitalVerifierat postnummerHong Kong, Hong Kong
- IRCCS Istituto Giannina GasliniVerifierat postnummerGenoa, Italy
Vanliga frågor
What is FOP?
FOP (Fibrodysplasia Ossificans Progressiva) is a rare condition where soft tissues, like muscles, turn into bone over time, causing pain and limiting movement.
What is garetosmab?
Garetosmab is a new investigational drug being tested to see if it can help treat FOP.
Vad är en placebo?
A placebo is a substance that looks exactly like the study drug but doesn't contain any active medication. It's used to compare against the real drug.
Kommer jag att veta om jag får läkemedlet eller placebon?
No, this study is 'blinded,' meaning neither you nor your study doctor will know whether you are receiving garetosmab or the placebo.
Vem finansierar denna studie?
The information provided doesn't state the specific funder, but typically such studies are funded by pharmaceutical companies or research organisations.
Hur du får reda på mer
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.